California - based healthcare is set to expand its genomics testing and diagnostic products range after raising $ 45 m in a series of funding round , led by Chinese firm Fortune Fountain Capital . DiaCarta CEO Aiguo Zhang has big plans for the cash injection , including establishing global clinical study programmes for non - invasive early cancer detection and commercially launching its first colorectal cancer detection assay . The company raised $ 8 m In a round A round more than three years ago .
California-based DiaCarta is set to expand its genomics testing and diagnostics products range after raising $45m in a series B funding round, led by Chinese firm Fortune Fountain Capital. DiaCarta CEO Aiguo Zhang has big plans for the cash injection, including establishing global clinical study programmes for non-invasive early cancer detection and commercially launching its ColoScape colorectal cancer detection assay. The company raised $8m In a series A round more than three years ago.